StockNews.com assumed coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Free Report) in a research report released on Friday. The firm issued a hold rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright reaffirmed a neutral rating on shares of TRACON Pharmaceuticals in a report on Monday, July 1st.
Check Out Our Latest Research Report on TRACON Pharmaceuticals
TRACON Pharmaceuticals Price Performance
TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) last announced its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) EPS for the quarter. The business had revenue of $0.06 million for the quarter.
About TRACON Pharmaceuticals
TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.
Further Reading
- Five stocks we like better than TRACON Pharmaceuticals
- Consumer Staples Stocks, Explained
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- How to Read Stock Charts for Beginners
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- Breakout Stocks: What They Are and How to Identify Them
- RPM International Thrives in Rate-Cut Driven Construction Rally
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.